###begin article-title 0
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
Inducible gene inactivation in neurons of the adult mouse forebrain
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 493 495 493 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 665 668 665 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 758 761 754 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 463 468 <span type="species:ncbi:9606">human</span>
The analysis of the role of genes in important brain functions like learning, memory and synaptic plasticity requires gene inactivation at the adult stage to exclude developmental effects, adaptive changes or even lethality. In order to achieve temporally controlled somatic mutagenesis, the Cre/loxP-recombination system has been complemented with the tamoxifen-inducible fusion protein consisting of Cre recombinase and the mutated ligand binding domain of the human estrogen receptor (CreERT2). To induce recombination of conditional alleles in neurons of the adult forebrain, we generated a bacterial artificial chromosome-derived transgene expressing the CreERT2 fusion protein under control of the regulatory elements of the CaMKIIalpha gene (CaMKCreERT2 transgene).
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 84 87 84 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 111 114 111 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 552 555 552 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 467 471 <span type="species:ncbi:10090">mice</span>
We established three mouse lines harboring one, two and four copies of the CaMKCreERT2 transgene. The CaMKCreERT2 transgene displayed reliable and copy number-dependent expression of Cre recombinase specifically in neurons of the adult forebrain. Using Cre reporter mice we show very low background activity of the transgene in absence of the ligand and efficient induction of recombination upon tamoxifen treatment in all three lines. In addition, we demonstrate in mice harboring two conditional glucocorticoid receptor (GR) alleles and the CaMKCreERT2 transgene spatially restricted loss of GR protein expression in neurons of the adult forebrain upon tamoxifen treatment.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 122 127 <span type="species:ncbi:10090">mouse</span>
This is to our knowledge the first approach allowing highly efficient inducible gene inactivation in neurons of the adult mouse forebrain. This new approach will be a useful tool to dissect the function of specific genes in the adult forebrain. Effects of gene inactivation on pre- and postnatal brain development and compensatory mechanisms elicited by an early onset of gene inactivation can now be excluded.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 18 23 <span type="species:ncbi:10090">mouse</span>
The generation of mouse mutants harboring targeted inactivation of desired genes using homologous recombination in embryonic stem cells is a powerful tool to analyze their role in complex brain functions such as learning and memory, synaptic plasticity as well as neurogenesis and neuronal cell death [1-3]. However, inactivation of genes in the germline often results in a lethal phenotype that prevents further analysis of the targeted gene in the adult brain.
###end p 9
###begin p 10
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 503 504 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 238 254 <span type="species:ncbi:10678">bacteriophage P1</span>
To bypass early lethality and to analyze functions of a gene particularly in the adult brain the Cre/loxP-recombination system, that allows to conditionally ablate a defined gene, was implemented. In the Cre/loxP-recombination system the bacteriophage P1 Cre recombinase is expressed in a cell-type specific manner. In the Cre expressing cells the recombinase mediates excision of an essential part of the targeted gene that has been flanked by two loxP recognition sequences in the same orientation [4,5].
###end p 10
###begin p 11
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1229 1231 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1232 1234 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1255 1264 1255 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1268 1276 1268 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1290 1293 1290 1293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1382 1384 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1385 1387 1385 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1399 1402 1399 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1470 1472 1470 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1473 1475 1473 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1546 1548 1546 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1563 1565 1563 1565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1566 1568 1566 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1593 1595 1593 1595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1623 1625 1623 1625 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 356 361 <span type="species:ncbi:4932">yeast</span>
###xml 1687 1691 <span type="species:ncbi:10090">mice</span>
To drive the expression of Cre in the brain, in most cases short promotor fragments of genes with desired expression pattern have been cloned in front of a Cre cassette in a plasmid [6-8]. Since plasmid-derived transgenes show copy number-independent and often mosaic and ectopic expression [9,10] the use of BAC (bacterial artificial chromosome)- or YAC (yeast artificial chromosome)-derived transgenes is in favor. In contrast to plasmids, BAC and YAC vectors harbor large genomic regions containing almost all regulatory elements of the gene locus that was chosen to drive Cre expression. However, a given gene locus may not only be expressed in the adult brain, but also during pre- and postnatal development [11]. To overcome the necessity to find a gene locus that is active only at a desired time-point during development or at the adult stage fusion proteins consisting of Cre recombinase and a mutated ligand-binding domain (LBD) of a steroid hormone receptor have been developed to achieve ligand-dependent Cre activity. The mutated LBD retains the fusion protein in the cytoplasm and upon binding of a synthetic ligand it translocates into the nucleus, where it mediates the excision of the loxP-flanked DNA sequence [12-15]. It has been shown in vitro and in vivo that the CreERT2 is the most potent Cre fusion protein with low leakiness and highly efficient induction [13,16]. The CreERT2 fusion protein was so far applied in peripheral cell-types/tissues [17-19] and within the nervous system in oligodendrocytes and Schwann cells [20], astrocytes [21-23] and neural stem cells [24]. The verification of CreERT2-mediated recombination was only performed using Cre reporter mice. Cre reporter data are very helpful to detect ligand-independent (background) activity of the Cre and robust induction of recombination, but this type of analysis does not allow to assess incomplete induction. To analyze the extent of gene inactivation, expression analysis of the protein encoded by the targeted gene is mandatory.
###end p 11
###begin p 12
###xml 212 215 208 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 325 328 321 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 532 534 524 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 862 865 854 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 510 515 <span type="species:ncbi:10090">mouse</span>
In order to target neurons in the adult brain that participate in important brain functions like learning, memory and long term potentiation, we have chosen the CaMKIIalpha gene regulatory elements to drive CreERT2 expression in the forebrain including limbic structures like hippocampus and amygdala. We introduced the CreERT2 fusion protein in frame at the ATG of the CaMKIIalpha gene present on a large genomic fragment in a BAC vector using homologous recombination in bacteria. The established transgenic mouse lines (CaMKCreERT2) displayed copy number-dependent, forebrain-specific expression of the Cre recombinase. Using this transgene we show efficient forebrain-specific induction of recombination upon tamoxifen treatment with very low background activity in absence of the ligand restricted to the hippocampus. Unlike previous studies utilizing CreERT2 mediated recombination in the brain, we demonstrate for the first time by expression analysis of the protein encoded by the targeted gene, the high efficiency of this inducible gene inactivation system.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
###xml 45 47 45 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
Copy number-dependent expression of the CreERT2-fusion protein in the adult mouse hippocampus
###end title 14
###begin p 15
###xml 146 149 146 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 249 251 245 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 263 266 259 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 392 394 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 395 397 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 605 608 601 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 676 679 672 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 999 1001 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1027 1030 1019 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1085 1088 1077 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1145 1147 1133 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1190 1192 1178 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1442 1444 1422 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 216 221 <span type="species:ncbi:10090">mouse</span>
###xml 362 367 <span type="species:ncbi:9606">human</span>
###xml 977 982 <span type="species:ncbi:10090">mouse</span>
###xml 1418 1423 <span type="species:ncbi:10090">mouse</span>
To achieve inducible recombination of conditional alleles in neurons of the adult brain, we generated a BAC-derived transgene expressing the CreERT2 fusion protein under the control of the regulatory elements of the mouse CaMKIIalpha gene (CaMKCreERT2). The CreERT2 fusion protein consists of the Cre recombinase and a mutated ligand binding domain (LBD) of the human estrogen receptor (ER) [13,16]. The ER-LBD contains a nuclear localization signal that is unmasked upon ligand binding. Two point mutations in the ER-LBD allow binding of the synthetic ligand tamoxifen and prevent activation of the CreERT2 by endogenous estradiol. Therefore, the unliganded form of the CreERT2 fusion protein resides in the cytoplasm and upon tamoxifen binding it translocates into the nucleus and mediates site-specific recombination. We selected a BAC vector harboring a genomic insert containing the CaMKIIalpha gene locus with a 43 kb 5'upstream and a 100 kb 3'downstream region from the mouse genome project [25]. To obtain the CaMKCreERT2 transgene we inserted the coding sequence for the CreERT2 fusion protein at the ATG of the CaMKIIalpha locus (Fig. 1A) by homologous recombination in bacteria [26]. Using an equivalent genomic fragment containing the CaMKIIalpha gene our group has already generated a constitutive transgene (CaMKCre) that expresses the Cre recombinase under the control of the regulatory elements of the mouse CaMKIIalpha gene [27].
###end p 15
###begin p 16
###xml 101 103 101 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 0 154 0 154 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Copy number-dependent transgene expression and tamoxifen-dependent nuclear translocation of the CreER<sup>T2</sup>-fusion protein in neurons of the adult hippocampus</bold>
###xml 191 193 191 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 608 611 600 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 908 911 900 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1108 1111 1096 1099 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 325 330 <span type="species:ncbi:10090">mouse</span>
Copy number-dependent transgene expression and tamoxifen-dependent nuclear translocation of the CreERT2-fusion protein in neurons of the adult hippocampus. (A) The cassette encoding the CreERT2-fusion protein was inserted in frame at the ATG of the CaMKIIalpha gene present on a large DNA fragment of a BAC vector containing mouse genomic DNA by homologous recombination in bacteria. The genomic insert of the BAC vector contained a 43 kb 5'-upstream and a 100 kb 3'-downstream region of the CaMKIIalpha gene. (B-G) Immunohistochemical staining of pyramidal neurons in the hippocampal CA1 region of CaMKCreERT2 transgenic animals with different transgene copy numbers using an antibody against Cre recombinase revealed non-nuclear localization of the Cre recombinase in vehicle-injected animals (B, D, F) and nuclear localization in animals 12 hours after injection of 1 mg tamoxifen (C, E, G). The CaMKCreERT2 transgene copy number was determined by Southern blot analysis using a probe that detects restriction fragments of different sizes for the endogenous CaMKIIalpha gene (upper band) and the CaMKCreERT2 transgene (lower band) (H, I, J).
###end p 16
###begin p 17
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1H&#8211;J</xref>
###xml 500 503 500 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 761 764 761 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 807 812 807 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B, D</xref>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1F</xref>
###xml 935 940 935 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C, E</xref>
###xml 945 947 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1G</xref>
###xml 1068 1071 1068 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1199 1203 1199 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B&#8211;J</xref>
###xml 1259 1262 1259 1262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 106 111 <span type="species:ncbi:10090">mouse</span>
The modified genomic insert was released and separated from the BAC backbone and then introduced into the mouse germline by oocyte injection. Transgenic founder animals were identified by PCR and dot blot analysis of tail DNA. The F1 progeny was used to determine the copy number of the transgene by Southern blot (Fig. 1H-J). Three lines harboring either one, two or four copies of the transgene were chosen for further analyses. We investigated the expression and nuclear translocation of the CreERT2 fusion protein upon tamoxifen treatment by immunohistochemistry on hippocampal vibratome sections using an anti-Cre antibody. Transgenic animals were injected with either tamoxifen or vehicle 12 hours before dispatch. In the vehicle-treated animals the CreERT2 protein was located in the cytoplasm (Fig. 1B, D and 1F), whereas tamoxifen-treated animals displayed nuclear localization of the Cre recombinase in the hippocampus (Fig. 1C, E and 1G). In addition, copy number-dependent expression was observed, the four-copy line showed stronger expression of the CreERT2 fusion protein than the two-copy line which displayed a stronger Cre expression in the hippocampus than the one-copy line (Fig. 1B-J). Nuclear translocation and copy number-dependent CreERT2 expression was also observed in other brain regions, e.g. cortex (data not shown).
###end p 17
###begin title 18
Targeted recombination in adult forebrain regions upon tamoxifen induction
###end title 18
###begin p 19
###xml 16 18 16 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 186 189 186 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 318 321 318 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 532 535 532 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
To assess the ERT2-mediated control of Cre activity in absence of the ligand in forebrain neurons and to examine the efficiency of tamoxifen-induced Cre-mediated recombination, CaMKCreERT2 mice with different transgene copy numbers were crossed with ROSA26 Cre reporter mice (R26R allele) [28] to obtain R26R/CaMKCreERT2 mice. The Cre reporter line harbors a knock-in of a lacZ gene preceded by a stop cassette, flanked by two recognition sequences (loxP) for the Cre recombinase, in the ROSA26 locus. Upon tamoxifen treatment CreERT2 translocates into the nucleus and deletes the stop cassette thereby permitting beta-galactosidase expression.
###end p 19
###begin p 20
###xml 14 17 14 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 256 259 253 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 579 581 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
R26R/CaMKCreERT2 mice were injected twice per day with either tamoxifen or vehicle for five consecutive days. Whole mount samples of the adult brain from the one-, two- or four-copy line were analyzed for beta-galactosidase activity. Determination of CreERT2 activity in absence of the ligand revealed that ten weeks old vehicle-injected animals of all three transgenic lines showed very little beta-galactosidase activity within the hippocampus only. Using whole mount staining we could not detect substantial differences between one, two and four copies of the transgene (Fig. 2A, two-copy line). After tamoxifen treatment in all three lines beta-galactosidase activity was most prominent in the cortex and hippocampus. The one-copy line showed less intense staining than the two- and four-copy lines. However, no apparent difference was observed between the two-copy and the four-copy line (data not shown). In all three lines no beta-galactosidase activity was detected in other organs than the brain after tamoxifen induction (data not shown).
###end p 20
###begin p 21
###xml 5 8 5 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 0 172 0 168 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CreER<sup>T2 </sup>fusion protein expression driven by the regulatory elements of the CaMKII&#945; gene allows targeting of specific regions in the adult brain upon tamoxifen treatment</bold>
###xml 303 306 296 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 331 333 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 635 638 625 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1176 1179 1163 1166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1498 1502 1485 1489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox</sup>
###xml 1535 1542 1522 1529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/wt</sup>
###xml 1576 1583 1563 1570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/wt</sup>
###xml 1593 1595 1580 1582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 1900 1905 1887 1892 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox </sup>
###xml 1915 1918 1902 1905 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 1977 1982 1964 1969 <sup xmlns:xlink="http://www.w3.org/1999/xlink">null </sup>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 1447 1451 <span type="species:ncbi:10090">mice</span>
CreERT2 fusion protein expression driven by the regulatory elements of the CaMKIIalpha gene allows targeting of specific regions in the adult brain upon tamoxifen treatment. (A, B) beta-galactosidase staining of brain slices revealed that animals harboring a ROSA26 Cre reporter allele and the CaMKCreERT2 transgene (R26R/CaMKCreERT2, two copies) show low Cre activity in absence of the ligand only within the hippocampus (Hc) (A), but strong staining within the cortex (Co) and hippocampus (Hc) upon tamoxifen treatment (B). (D-F) Analysis of beta-galactosidase positive neurons using cryosections of the hippocampus of R26R/CaMKCreERT2 mice revealed sparse recombination in the granular neurons of the dentate gyrus (DG) and in hippocampal neurons of the CA1 region in the absence of tamoxifen. (C) beta-galactosidase staining of a brain slice isolated from an animal harboring a ROSA26 Cre reporter allele and the constitutive CaMKCre transgene (R26R/CaMKCre) revealed recombination in the hippocampus and cortex as well as recombination in olfactory bulbs (Ob), striatum (St) and cerebellum (Ce). (G-I) Recombination of a conditional GR allele achieved using the CaMKCreERT2 transgene (two copies) plus tamoxifen treatment (2 x 1 mg tamoxifen for five consecutive days) is comparable to recombination obtained using the constitutive CaMKCre transgene. Recombination levels detected in distinct brain regions (Co, Hc, Ht = hypothalamus, Ce) of mice heterozygous for the conditional GR allele (GRflox) and either the constitutive (GRflox/wt/CaMKCre) (I) or the inducible (GRflox/wt/CaMKCreERT2, tamoxifen-treated) (G) Cre transgene (two copies) were determined using Southern blot analysis. The Southern blot strategy is depicted in (H), black boxes represent exons three and four of the GR gene, the arrowheads the loxP sites and S marks SacI recognition sites. The probe detects in case of the GRflox and the GRwt allele a DNA fragment of similar size and in case of the GRnull allele a smaller DNA fragment. The bands were quantified by phosphoimager and the percentage of recombination for each region is indicated. Animals for Cre reporter and Southern blot analysis were treated with 1 mg tamoxifen or vehicle twice a day for five consecutive days and sacrificed ten days after the last injection.
###end p 21
###begin p 22
###xml 313 316 313 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 526 530 526 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D&#8211;F</xref>
###xml 316 320 <span type="species:ncbi:10090">mice</span>
Since the use of the minimal number of transgene copies that allow efficient recombination upon tamoxifen induction is desired, we only characterized for the two-copy line the activity in absence of tamoxifen ("background") in more detail. At the cellular level, using cryosections, vehicle-treated R26R/CaMKCreERT2 mice of the two-copy line displayed only few granular neurons in the dentate gyrus and even less pyramidal neurons in the CA1 region of the hippocampus that underwent recombination of the reporter allele (Fig. 2D-F).
###end p 22
###begin p 23
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 244 247 241 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 345 347 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 352 354 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 475 477 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 554 557 551 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 621 624 618 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 720 722 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 769 772 766 769 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 852 855 849 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 277 281 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 855 870 <span type="species:ncbi:10090">transgenic mice</span>
###xml 908 912 <span type="species:ncbi:10090">mice</span>
In order to compare the spatial activity of the inducible CaMKCreERT2 transgene with the constitutive CaMKCre transgene, beta-galactosidase stained brain whole mount samples of adult R26R/CaMKCre mice were analyzed as well. Both, R26R/CaMKCreERT2 (two copies) and R26R/CaMKCre mice showed extensive recombination in hippocampus and cortex (Fig. 2B and 2C). However, the constitutive transgene caused additional recombination in olfactory bulbs, striatum and cerebellum (Fig. 2C). Immunohistochemical staining for Cre revealed a strong expression of CreERT2 protein in those regions showing recombination in R26R/CaMKCreERT2 mice (e.g. hippocampus, cortex). As shown for the constitutive CaMKCre line at the adult stage [27], we could detect only very low level of CreERT2 expression in striatum and thalamus and no expression in cerebellum of CaMKCreERT2 transgenic mice (data not shown). Using Cre reporter mice we did not observe Cre-mediated recombination in any of these regions after tamoxifen application (data not shown).
###end p 23
###begin p 24
###xml 100 103 100 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 285 289 285 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox</sup>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 333 340 333 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/wt</sup>
###xml 374 381 374 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/wt</sup>
###xml 391 393 391 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 659 663 659 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2G&#8211;I</xref>
###xml 771 776 771 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox </sup>
###xml 808 811 808 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2G</xref>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2I</xref>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
To quantify and compare recombination evoked by the constitutive CaMKCre transgene and the CaMKCreERT2 transgene, induced with 1 mg tamoxifen twice per day for five consecutive days, at the DNA level by Southern blot, we generated animals heterozygous for the conditional GR allele (GRflox) [29] harboring either the constitutive (GRflox/wt/CaMKCre) or the inducible Cre (GRflox/wt/CaMKCreERT2, two copies) transgene respectively. The analysis of adult samples of different brain regions revealed that the areas showing recombination using Cre reporter mice (e.g. hippocampus and cortex) display a comparable degree of recombination for both transgenes (Fig. 2G-I). In case of the cerebellum we detected, as expected from the Cre reporter data, no recombination of the GRflox allele for the induced CaMKCreERT2 transgene, but distinct recombination for the constitutive CaMKCre transgene (Fig. 2G and 2I).
###end p 24
###begin title 25
###xml 97 100 97 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
Ablation of GR protein expression in the adult brain upon tamoxifen treatment using the CaMKCreERT2 transgene
###end title 25
###begin p 26
###xml 69 71 69 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 202 211 202 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 221 224 221 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 227 238 227 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2</sup>
###xml 277 280 277 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 309 321 309 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 620 623 620 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 671 676 671 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C, F</xref>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3I</xref>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3L</xref>
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3O</xref>
###xml 891 894 891 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 962 973 962 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B, E, H, K</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3N</xref>
###xml 1021 1032 1021 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A, D, G, J</xref>
###xml 1037 1039 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3M</xref>
###xml 1059 1062 1059 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1139 1142 1139 1142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1407 1410 1407 1410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1591 1603 1591 1603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 1010 1014 <span type="species:ncbi:10090">mice</span>
###xml 1603 1607 <span type="species:ncbi:10090">mice</span>
To demonstrate at the cellular level that the tamoxifen-induced CreERT2-mediated recombination of a targeted gene results in complete protein loss within specific populations of neurons, we generated GRflox/flox/CaMKCreERT2 (GRCaMKCreERT2) mice with two copies of the CaMKCreERT2 transgene. Eight weeks old GRCaMKCreERT2 mice were treated twice per day either with 1 mg tamoxifen or vehicle for five consecutive days and were sacrificed ten days after tamoxifen application. In addition, the mice were injected with 1 mg tamoxifen 12 hours before dispatch to visualize Cre expression. Immunohistochemistry revealed CreERT2 expression in the cortex, the hippocampus (Fig. 3C, F and 3I) as well as in the hypothalamic paraventricular nucleus (PVN) (Fig. 3L) and basolateral amygdala, whereas the central amygdala was spared (Fig. 3O). Accordingly, in neurons of these regions with strong CreERT2 expression, tamoxifen-treated animals show loss of GR protein (Fig. 3B, E, H, K and 3N) compared to vehicle-treated mice (Fig. 3A, D, G, J and 3M). Analysis of CreERT2 and GR protein expression in other forebrain structures revealed strong CreERT2 expression and the corresponding GR protein loss in the lateral septum and in the medial preoptic area, whereas in the striatum only weak Cre expression and no visible loss of GR protein were detectable (data not shown). Even though Cre reporter data revealed CreERT2 activity in absence of the ligand in the hippocampus, the background activity is much too low to allow the detection of a visible loss of GR protein expression in vehicle-treated GRCaMKCreERT2 mice in comparison to wild-type animals (data not shown).
###end p 26
###begin p 27
###xml 0 88 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ablation of GR protein expression in neurons of the adult brain upon tamoxifen treatment</bold>
###xml 159 163 159 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox</sup>
###xml 199 202 199 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 215 227 215 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 322 334 322 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 481 484 481 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 527 539 527 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 578 581 578 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1155 1158 1155 1158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 685 689 <span type="species:ncbi:10090">mice</span>
###xml 1043 1058 <span type="species:ncbi:10090">transgenic mice</span>
Ablation of GR protein expression in neurons of the adult brain upon tamoxifen treatment. Vibratome-sections of mice homozygous for a conditional GR allele (GRflox) and heterozygous for the CaMKCreERT2 transgene (GRCaMKCreERT2 mice) have been analyzed by immunohistochemistry. GR protein is expressed in vehicle-treated GRCaMKCreERT2 mice (A, D, G, J, M), whereas loss of GR expression upon tamoxifen treatment is observed in brain regions (B, E, H, K, N) that display strong CreERT2 expression (C, F, I, L, O). The analyzed GRCaMKCreERT2 mice harbor two copies of the CaMKCreERT2 transgene. Depicted are brain regions that have been identified as target regions using ROSA26 reporter mice and/or show strong GR expression in controls: cortex (A-C), CA1 region of the hippocampus (D-F), dentate gyrus (G-I), PVN (J-L) as well as central (ceA) and basolateral amygdala (blA) (M-O). The animals were injected with 1 mg tamoxifen or vehicle twice a day for five consecutive days and sacrificed ten days after the last injection. In addition, Cre transgenic mice were injected with tamoxifen 12 hours before analysis to obtain a nuclear staining for the CreERT2 fusion protein.
###end p 27
###begin p 28
###xml 78 81 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 151 154 151 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 355 358 355 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 431 434 431 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
To identify neuronal subtypes that are targeted in the cortex by the CaMKCreERT2 transgene, we performed immunohistochemical double-stainings for CreERT2 and markers for the two major neuronal subtypes present in the cortex. GABAergic interneurons were identified by GAD65/67 expression and glutamatergic neurons by VGLUT1 expression. We detected no CreERT2 protein expression in GABAergic interneurons, whereas expression of CreERT2 was present in glutamatergic neurons (data not shown).
###end p 28
###begin title 29
Effect of variations in transgene copy number and the applied tamoxifen dose on GR protein loss
###end title 29
###begin p 30
###xml 136 138 136 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 298 301 298 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 329 332 329 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 390 393 390 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 458 461 458 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 504 507 504 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 691 703 691 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 703 707 <span type="species:ncbi:10090">mice</span>
It has been shown previously that efficient induction of recombination is dependent on the applied tamoxifen dose and the level of CreERT2expression as well as on the particular conditional allele [16,20,30]. Thus it is possible, that different conditional alleles require different levels of CreERT2 activity. The level of CreERT2 activity is dependent on the expression level of the CreERT2 protein and on the availability of tamoxifen. Since the CaMKCreERT2 transgene shows copy number-dependent CreERT2 expression, we determined if we can detect an interrelation of transgene copy number and tamoxifen dose for the recombination evoked by this transgene. For this purpose, we injected GRCaMKCreERT2 mice harboring one, two or four copies of the transgene with 1 mg tamoxifen for five consecutive days once per day (5 mg) or twice per day (10 mg) and analyzed the loss of GR protein in hippocampus, cortex and PVN.
###end p 30
###begin p 31
###xml 132 141 132 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 250 262 250 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 481 484 481 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4E</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 656 668 656 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4F</xref>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4H</xref>
###xml 813 825 813 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4G</xref>
###xml 225 229 <span type="species:ncbi:10090">mice</span>
###xml 262 266 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
###xml 825 829 <span type="species:ncbi:10090">mice</span>
The immunohistochemical analysis of the pyramidal neurons of the hippocampal CA1 region revealed that tamoxifen-treated controls (GRflox/flox, Fig. 4A and 4B) show no difference in GR protein expression compared to wild-type mice (data not shown). GRCaMKCreERT2 mice with one copy of the transgene (Fig. 4C) show moderate loss of GR signal after applying 5 mg tamoxifen, but a strong decrease of GR protein if 10 mg tamoxifen were injected (Fig. 4D). Mutant mice with two CaMKCreERT2 copies treated with 5 mg tamoxifen also show a strong but incomplete loss of GR protein (Fig. 4E), comparable to one-copy animals treated with 10 mg tamoxifen (Fig. 4D). GRCaMKCreERT2 animals with two and four copies of the transgene display a complete loss of GR after injection of 10 mg tamoxifen (Fig. 4F and 4H). Likewise, GRCaMKCreERT2 mice with four copies of the transgene treated with 5 mg tamoxifen show complete GR loss in pyramidal neurons of the hippocampal CA1 region (Fig. 4G). The same correlation between copy number and ligand dose was observed in the dentate gyrus of the hippocampus and in the cortex (data not shown). However, in the PVN complete loss of GR signal was detected upon injection of 10 mg tamoxifen in the presence of two or four copies only, but none of the lines showed complete GR loss if 5 mg were applied (data not shown). Taken together, these data demonstrate that increasing copies of the transgene reduce the tamoxifen dose required to achieve recombination.
###end p 31
###begin p 32
###xml 5 7 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 0 119 0 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CreER<sup>T2</sup>-mediated recombination within the adult hippocampus depends on the transgene copy number and the tamoxifen dose</bold>
###xml 174 186 174 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 595 598 595 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 722 734 722 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 939 942 939 942 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 296 300 <span type="species:ncbi:10090">Mice</span>
###xml 734 738 <span type="species:ncbi:10090">mice</span>
###xml 942 957 <span type="species:ncbi:10090">transgenic mice</span>
CreERT2-mediated recombination within the adult hippocampus depends on the transgene copy number and the tamoxifen dose. Pyramidal neurons in the hippocampal CA1 region of GRCaMKCreERT2 and control animals were analyzed by immunohistochemistry on vibratome-sections using an antibody against GR. Mice were injected with tamoxifen for five consecutive days either once per day (5 mg) (A, C, E, G) or twice per day (10 mg) (B, D, F, H) and sacrificed ten days after the last injection. Treatment with 5 mg tamoxifen results in an incomplete loss of GR protein if one or two copies of the CaMKCreERT2 transgene are present (C, E), whereas four copies of the transgene are sufficient to induce complete GR protein loss (G). GRCaMKCreERT2 mice harboring two or four copies of the Cre transgene display complete loss of GR protein after injection of 10 mg tamoxifen (F, H). A visible but still incomplete loss of GR protein was seen in CaMKCreERT2 transgenic mice of the one-copy line treated with 10 mg tamoxifen (D) whereas tamoxifen-treated controls show no apparent loss of GR (A, B).
###end p 32
###begin p 33
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 397 400 397 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 532 535 532 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 596 608 596 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 700 709 700 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 999 1000 999 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1122 1134 1122 1134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 1329 1330 1329 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 877 881 <span type="species:ncbi:10090">mice</span>
###xml 1010 1014 <span type="species:ncbi:10090">mice</span>
###xml 1134 1138 <span type="species:ncbi:10090">mice</span>
It has been shown previously, that ablation of GR protein in neurons and glia cells results in a strong elevation of plasma corticosterone [29]. The adrenal release of corticosterone is controlled by the hypothalamic-pituitary-adrenal (HPA) axis. The feedback regulation of the HPA axis is mediated by GR at the level of the pituitary and PVN [31]. Since the PVN can be targeted with the CaMKCreERT2 transgene, the measurement of plasma corticosterone provides information about the efficiency of the GR ablation using the CaMKCreERT2 transgene. Therefore, we measured plasma corticosterone of GRCaMKCreERT2 animals harboring one, two or four copies of the transgene and their littermate controls (GRflox/flox) at the circadian trough. All animals were injected with 1 mg tamoxifen twice a day for five consecutive days and sacrificed six weeks after the treatment. The mutant mice from all three lines show, as expected, a significant elevation of plasma corticosterone compared to controls (Table 1). Mutant mice, harboring one copy of the transgene display a significant, but rather mild elevation of corticosterone. GRCaMKCreERT2 mice with two and four copies of the transgene exhibit an equivalent and compared to mutant animals with one copy of the transgene a stronger elevation of the morning corticosterone level (Table 1).
###end p 33
###begin p 34
###xml 65 77 65 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Plasma corticosterone level [ng/ml] of adult tamoxifen-treated GRCaMKCreERT2 mice at diurnal trough
###end p 34
###begin p 35
###xml 12 21 12 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 34 43 34 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 53 56 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
control = GRflox/flox, mutant = GRflox/flox/CaMKCreERT2 transgene
###end p 35
###begin p 36
* p < 0.05, control versus mutant
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
Brain-specific gene inactivation using the Cre/loxP-recombination system allows to investigate gene function in the adult brain in case the germline inactivation of the gene of interest causes lethality. However, most of the available brain-specific Cre-lines show onset of Cre expression before the development of the brain is completed [6,29,32]. Therefore, phenotypical changes can result from interferences during brain development and/or from deficiency of the respective protein in the adult brain [11].
###end p 38
###begin p 39
###xml 753 755 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 832 834 828 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 837 839 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1088 1090 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1113 1116 1105 1108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1158 1160 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1244 1246 1236 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1247 1249 1239 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1317 1319 1309 1311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 553 558 <span type="species:ncbi:9606">human</span>
###xml 1285 1290 <span type="species:ncbi:10090">mouse</span>
###xml 1382 1387 <span type="species:ncbi:10090">mouse</span>
To achieve a spatio-temporal control of Cre-mediated recombination in the adult brain, regulatory elements of the CaMKIIalpha gene have been already used to drive the expression of different Cre fusion proteins. The fusion of Cre recombinase with a modified ligand-binding domain (LBD) of a steroid hormone receptor (e.g. progesterone receptor or estrogen receptor) allows to regulate nuclear translocation and thereby activity of the Cre recombinase by administration of the cognate ligand. Expression of Cre recombinase fused to a mutated form of the human progesterone receptor-LBD resulted in incomplete recombination within the hippocampal cornu ammonis and the cortex upon RU 486 treatment, but no recombination was observed in the dentate gyrus [14]. The fusion of a mutated ligand-binding domain of the estrogen receptor (ERT2) [13] onto both ends of the Cre recombinase, expressed under the control of the regulatory elements of the CaMKIIalpha gene, resulted in very weak recombination efficiency (5%-10% in hippocampal pyramidal and granular neurons) upon tamoxifen treatment [33]. The fusion of one ERT2 to the C-terminal end of Cre recombinase [13] has been recently employed in oligodendrocytes, astrocytes and neural stem cells [20-24]. We have now generated transgenic mouse lines expressing the CreERT2fusion protein under the control of regulatory elements of the mouse CaMKIIalpha gene present on a large genomic DNA fragment isolated from a BAC library. This transgene allows highly efficient recombination of conditional genes in brain regions shown to be important for learning, memory and synaptic plasticity.
###end p 39
###begin title 40
###xml 13 16 13 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
The CaMKCreERT2 transgene displays forebrain-specific, copy number-dependent expression and permits inducible site-specific recombination
###end title 40
###begin p 41
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 696 699 692 695 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 619 624 <span type="species:ncbi:10090">mouse</span>
###xml 660 675 <span type="species:ncbi:10090">transgenic mice</span>
The use of plasmid-derived transgenes that contain small promoter fragments in front of an expression cassette results in copy number-independent transgene expression. In addition, variable degrees of ectopic and mosaic expression of the transgene is observed [9,10,34]. The use of BAC or YAC clones, that contain large regions of genomic DNA with almost all regulatory elements of the gene with desired expression in their native configuration, allows expression of the transgene that resembles the expression of the endogenous gene independent of the integration site [27,35,36]. Using the regulatory elements of the mouse CaMKIIalpha gene we have generated transgenic mice expressing the CreERT2 fusion protein in neurons of the adult forebrain. We obtained different lines harboring one, two or four copies of the transgene. As expected, the expression pattern of the transgene is identical in all analyzed transgenic lines and shows only copy number-dependent differences at the level of expression.
###end p 41
###begin p 42
###xml 88 91 88 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1536 1539 1527 1530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1665 1668 1656 1659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
Using the ROSA26 Cre reporter we demonstrated the effective temporal regulation of CreERT2 activity by tamoxifen treatment in all three lines. In absence of the ligand noteworthy constitutive recombination occurs only within the dentate gyrus. Application of tamoxifen results in strong recombination within forebrain regions like hippocampus and cortex. Using the two-copy line we compared the degree of recombination with the one elicited by the constitutive CaMKCre line. Analysis of beta-galactosidase stainings of double transgenic animals harboring a ROSA26 Cre reporter allele and the constitutively active CaMKCre revealed recombination in the entire brain. However, brain regions that show recombination in both, the constitutive and the inducible Cre transgene after tamoxifen treatment, display in the adult brain (ten weeks) a comparable degree of recombination when quantified by Southern blot. Since both transgenic lines show similar Cre expression, independent of the developmental stage, the observed differences in recombination pattern result from the different time period of nuclear Cre activity of both transgenes. Using a ROSA26 Cre reporter, we observe in case of the constitutive CaMKCre transgene the accumulated recombination and thereby beta-galactosidase staining in all cells where Cre was active during development and adulthood until dispatch. Therefore, brain regions that show no or only weak Cre expression at the adult stage can nevertheless show beta-galactosidase staining. In case of the CaMKCreERT2 transgene Cre is only transiently activated during the presence of tamoxifen. Thus the pattern of recombination reflects CreERT2 expression within this time period only.
###end p 42
###begin title 43
Inducible ablation of GR protein expression in the adult brain depends on the copy number of the Cre transgene and the tamoxifen dose
###end title 43
###begin p 44
###xml 38 41 38 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 98 110 98 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 139 142 139 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 242 254 242 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 443 446 443 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
We successfully employed the CaMKCreERT2 transgene in combination with a conditional GR allele (GRCaMKCreERT2 mice, two copies of the CreERT2 transgene) to achieve ablation of GR in neurons of the adult forebrain. Upon tamoxifen treatment, GRCaMKCreERT2 mice show loss of GR protein, whereas vehicle-treated mutants showed no alterations in GR expression compared to wild-type mice, reflecting the very low background activity of the CaMKCreERT2 transgene. In addition, we demonstrate for the hippocampus that an increase in transgene copy numbers allows the reduction of the tamoxifen dose required to achieve complete recombination.
###end p 44
###begin p 45
###xml 100 103 100 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 693 705 693 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CaMKCreERT2 </sup>
###xml 737 740 737 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 943 946 943 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1025 1027 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1142 1145 1142 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 705 709 <span type="species:ncbi:10090">mice</span>
Using the conditional GR allele we could show that using the two- or four-copy line of the CaMKCreERT2 transgene in combination with the injection of 1 mg tamoxifen twice per day for five consecutive days results in similar recombination efficiency, leading to complete loss of GR protein in the cortex, hippocampus, PVN and basolateral amygdala as well as a comparable increase of plasma corticosterone. Using the same tamoxifen dose the one-copy line displays only partial loss of GR protein in PVN and hippocampus resulting in a milder increase of plasma corticosterone. Since BAC-derived large genomic DNA fragments potentially carry additional genes we will use for further analyses of GRCaMKCreERT2 mice two copies of the CaMKCreERT2 transgene and apply 1 mg tamoxifen twice per day for five consecutive days. Moreover, we could induce MR protein loss upon the identical tamoxifen treatment in the brain regions targeted by the CaMKCreERT2 transgene using the two-copy line in combination with a conditional MR allele [11] (unpublished observation). However, other conditional alleles may require the use of four copies of the CaMKCreERT2 transgene in combination with the injection of 1 mg tamoxifen twice per day for five consecutive days, to achieve complete recombination.
###end p 45
###begin title 46
Conclusion
###end title 46
###begin p 47
###xml 27 29 27 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 120 123 116 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 424 427 420 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
The expression of the CreERT2-fusion protein under control of the regulatory elements of the CaMKIIalpha gene (CaMKCreERT2 transgene) allows inducible gene inactivation in neurons of the adult forebrain with very low background activity and highly efficient targeting upon tamoxifen treatment. The use of a BAC-based transgene resulted in a reliable and copy number-dependent transgene expression. By employing the CaMKCreERT2 transgene in combination with a conditional GR allele we were able to induce spatially and temporally restricted loss of GR protein dependent on transgene copy number and applied tamoxifen dose.
###end p 47
###begin title 48
Methods
###end title 48
###begin title 49
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 26 41 <span type="species:ncbi:10090">transgenic mice</span>
Generation of CaMKCreERT2 transgenic mice
###end title 49
###begin p 50
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 432 434 428 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 490 492 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 564 566 560 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 569 571 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 718 720 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 894 896 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 949 952 945 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 1212 1214 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1438 1440 1430 1432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2</sup>
###xml 1653 1657 1645 1649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox</sup>
###xml 1660 1662 1652 1654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 106 111 <span type="species:ncbi:10090">mouse</span>
###xml 247 252 <span type="species:ncbi:10090">mouse</span>
###xml 537 542 <span type="species:ncbi:9606">human</span>
###xml 1197 1202 <span type="species:ncbi:10090">mouse</span>
###xml 1368 1372 <span type="species:ncbi:10090">mice</span>
###xml 1396 1400 <span type="species:ncbi:10090">mice</span>
###xml 1442 1447 <span type="species:ncbi:10090">mouse</span>
###xml 1547 1562 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1598 1602 <span type="species:ncbi:10090">mice</span>
###xml 1611 1615 <span type="species:ncbi:10090">mice</span>
A bacterial artificial chromosome (BAC) harboring 143 kb of genomic DNA (RP24-243J21) was chosen from the mouse genome project [25]. The genomic DNA-fragment contains, similar to the one used to generate a constitutive CaMKCre transgene [27], the mouse CaMKIIalpha locus with a 43 kb 5'upstream and a 100 kb 3'downstream region. This BAC was modified by homologous recombination to insert a cassette encoding a fusion protein (CreERT2) consisting of a codon-improved Cre recombinase (Cre) [37] and a mutated ligand-binding domain of the human estrogen receptor (ERT2) [13] as well as an ampicillin resistance cassette flanked by two FRT sites. The linear construct was electroporated into heat-induced EL250 bacteria [26] harboring the BAC. Clones with the recombinant BAC were induced with L-arabinose to express Flp recombinase that results in deletion of the ampicillin resistance cassette [26]. The modified genomic fragment containing the CreERT2 knock-in at the ATG of the CaMKIIalpha gene was separated from the BAC backbone by NotI digestion and subsequent preparative pulse-field gel electrophoresis. The DNA was purified from the gel slice and microinjected into the pronucleus of FVB/N mouse oocytes [38]. Transgenic offspring (founder) was identified by dot blot of tail DNA. A fragment of the coding sequence of Cre was labeled and used as probe. Founder mice were bred with C57Bl/6 mice to generate BAC-transgenic (CaMKCreERT2) mouse lines. Three different lines with one, two and four copies of the transgene were analyzed. The Cre-transgenic mice were bred with ROSA26 Cre reporter mice or with mice harboring a conditional GR allele (GRflox) [29] to generate the respective genotypes used for the experiments.
###end p 50
###begin title 51
Animal-treatment
###end title 51
###begin p 52
###xml 645 655 644 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox </sup>
###xml 671 680 670 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 690 693 689 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 386 390 <span type="species:ncbi:10090">mice</span>
###xml 702 706 <span type="species:ncbi:10090">mice</span>
Tamoxifen (Sigma) was dissolved in sunflower seed oil/ethanol (10:1) mixture at a final concentration of 10 mg/ml. Eight weeks old mice were injected intraperitoneally with 1 mg of tamoxifen either once or twice per day for five consecutive days. Control animals were injected with 100 mul of sunflower seed oil/ethanol mixture (vehicle). If not otherwise specified, control and mutant mice possessed the same genotype, but differed in the treatment (control: vehicle, mutant: tamoxifen). Experimental animals for immunohistochemistry and Cre reporter analysis were sacrificed ten days after the last injection. For corticosterone measurement GRflox/flox (control) and GRflox/flox/CaMKCreERT2 (mutant) mice were both treated with 1 mg tamoxifen twice a day for five consecutive days and were sacrificed six weeks after the last injection to allow recovery from the tamoxifen treatment.
###end p 52
###begin title 53
Corticosterone measurement
###end title 53
###begin p 54
###xml 546 548 544 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
To determine plasma corticosterone, adult mice (14 weeks) were housed individually one week before the experiment (light on 9:00 - 21:00). Blood sampling was performed in the morning (starting at 10:00) by bleeding after decapitation, with the time from first handling to decapitation not exceeding 20 s, to determine plasma corticosterone at circadian trough. Plasma corticosterone was measured using a commercially available RIA kit (MP Biomedicals). Results are presented as mean +/- SEM and were analyzed using unpaired, two-tailed Student's t test.
###end p 54
###begin title 55
Immunohistochemistry and beta-galactosidase staining
###end title 55
###begin p 56
###xml 447 449 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
For immunohistochemical analysis, the dissected brains were postfixed with 4% paraformaldehyde at 4degreesC for 72 hrs. Coronal sections with a thickness of 50 mum were performed using a vibratome (Microm). The floating sections were processed for immunohistochemistry using the VECTASTAIN ABC system (Vector Laboratories) and diaminobenzidine (Sigma) incubation. Following primary antibodies have been used: polyclonal anti-Cre (diluted 1:3000) [14] and polyclonal anti-GR (diluted 1:1000) (Santa Cruz Biotechnology).
###end p 56
###begin p 57
###xml 187 188 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 312 313 309 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 361 363 358 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 370 371 367 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 381 383 378 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 390 391 387 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
For beta-galactosidase whole mount stainings, dissected brains were cut with a razor blade in the appropriate planes, washed three times with washing buffer (1 x PBS, 5 mM EGTA, 2 mM MgCl2, 0.01% sodium-deoxycholat and 0.02% NP-40) and were subsequently stained with X-gal staining solution (5 mM EGTA, 2 mM MgCl2, 0.01% sodium-deoxycholat, 0.02% NP-40, 10 mM K3 [Fe(CN)6], 10 mM K4 [Fe(CN)6] and 0.5 mg/ml X-gal in 1 x PBS) at 37degreesC over night. After the staining slices were postfixed with 4% paraformaldehyde at 4degreesC over night and kept in 1 x PBS at 4degreesC for analysis. For beta-galactosidase staining of cryosections, dissected brains were frozen in O.C.T. compound (Tissue Tek, Sakura Finetek) on ethanol/dry ice and 10 mum sagital cryosections were prepared. Sections were fixed 10 min in 4% paraformaldehyde and beta-galactosidase staining was performed as described for whole mount samples. Afterwards, sections were counterstained with nuclear fast red (Sigma) and mounted with Eukitt (O. Kindler).
###end p 57
###begin title 58
Analysis of transgene copy numbers and quantification of recombination
###end title 58
###begin p 59
###xml 225 227 217 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Transgene copy number was determined by Southern blot of tail DNA digested with BamHI and hybridized with a DNA probe detecting sequences in the CaMKIIalpha promotor region. The probe was labeled by random-priming with alpha-32PdCTP. Relative band intensities were assessed by phosphoimager (Fuji) and the band originating from the endogenous CaMKIIalpha gene was calculated as two copies.
###end p 59
###begin p 60
###xml 192 197 192 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox </sup>
###xml 207 210 207 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 272 277 272 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">null </sup>
###xml 436 441 436 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">null </sup>
###xml 500 504 500 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox</sup>
###xml 507 510 507 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 521 526 521 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">null </sup>
For analysis of Cre-mediated recombination, genomic DNA was isolated from different brain areas. The DNA was digested with SacI, blotted and hybridized with a probe detecting in case of the GRflox and the GRwt allele a fragment of similar size (7 kb) and in case of the GRnull allele a smaller fragment (4.8 kb). Signals were quantified by phosphoimager (Fuji) and percentage of recombination is calculated as signal intensity of the GRnull band divided by the sum of the signal intensities of the GRflox/GRwt band and GRnull band.
###end p 60
###begin title 61
Authors' contributions
###end title 61
###begin p 62
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
###xml 322 325 322 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T2 </sup>
GE participated in the generation of the CaMKCreERT2 transgenic lines and coordinated the study, carried out the histological and functional characterization of the lines and wrote the manuscript. GS contributed to the design of the study and to the draft of the manuscript. SB conceived the study, generated the CaMKCreERT2 transgene and designed the manuscript. All authors read and approved the final manuscript.
###end p 62
###begin title 63
Acknowledgements
###end title 63
###begin p 64
We thank Joachim Elzer for his technical support as well as Heike Alter and Steffi Stotz for microinjection. This work was supported by the "Deutsche Forschungsgemeinschaft" through Sonderforschungsbereiche 488 and 636, GRK 791/1.02, and Sachbeihilfe Schu 51/7-2, by the "Fonds der Chemischen Industrie", the European Union through grant LSHM-CT-2005-018652 (CRESCENDO) and the Bundesministerium fur Bildung und Forschung (BMBF) through NGFN grants FZK 01GS01117, 01GS0477 and KGCV1/01GS0416.
###end p 64
###begin article-title 65
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
Transgenic and knockout databases: behavioral profiles of mouse mutants
###end article-title 65
###begin article-title 66
###xml 32 36 <span type="species:ncbi:10090">mice</span>
List of transgenic and knockout mice: behavioral profiles
###end article-title 66
###begin article-title 67
Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain
###end article-title 67
###begin article-title 68
Cre recombinase: the universal reagent for genome tailoring
###end article-title 68
###begin article-title 69
Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting
###end article-title 69
###begin article-title 70
###xml 62 67 <span type="species:ncbi:10090">mouse</span>
Cre-mediated transgene activation in the developing and adult mouse brain
###end article-title 70
###begin article-title 71
Disruption of CREB function in brain leads to neurodegeneration
###end article-title 71
###begin article-title 72
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
Subregion- and cell type-restricted gene knockout in mouse brain
###end article-title 72
###begin article-title 73
###xml 154 158 <span type="species:ncbi:10090">mice</span>
Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice
###end article-title 73
###begin article-title 74
Enhanced odor discrimination and impaired olfactory memory by spatially controlled switch of AMPA receptors
###end article-title 74
###begin article-title 75
Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity
###end article-title 75
###begin article-title 76
Regulation of Cre recombinase activity by the synthetic steroid RU 486
###end article-title 76
###begin article-title 77
Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains
###end article-title 77
###begin article-title 78
Inducible site-specific recombination in the brain
###end article-title 78
###begin article-title 79
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
Temporally controlled targeted somatic mutagenesis in the mouse brain
###end article-title 79
###begin article-title 80
Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases
###end article-title 80
###begin article-title 81
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice expressing a ligand-inducible cre recombinase in osteoblasts and odontoblasts: a new tool to examine physiology and disease of postnatal bone and tooth
###end article-title 81
###begin article-title 82
Spatiotemporal gene control by the Cre-ERT2 system in melanocytes
###end article-title 82
###begin article-title 83
Efficient recombination in pancreatic islets by a tamoxifen-inducible Cre-recombinase
###end article-title 83
###begin article-title 84
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Tamoxifen-inducible glia-specific Cre mice for somatic mutagenesis in oligodendrocytes and Schwann cells
###end article-title 84
###begin article-title 85
Temporal control of gene recombination in astrocytes by transgenic expression of the tamoxifen-inducible DNA recombinase variant CreERT2
###end article-title 85
###begin article-title 86
Early postnatal astroglial cells produce multilineage precursors and neural stem cells in vivo
###end article-title 86
###begin article-title 87
Inducible gene deletion in astroglia and radial glia--a valuable tool for functional and lineage analysis
###end article-title 87
###begin article-title 88
Temporal regulation of Cre recombinase activity in neural stem cells
###end article-title 88
###begin article-title 89
Ensembl
###end article-title 89
###begin article-title 90
###xml 64 80 <span type="species:ncbi:562">Escherichia coli</span>
An efficient recombination system for chromosome engineering in Escherichia coli
###end article-title 90
###begin article-title 91
A CamKIIalpha iCre BAC allows brain-specific gene inactivation
###end article-title 91
###begin article-title 92
Generalized lacZ expression with the ROSA26 Cre reporter strain
###end article-title 92
###begin article-title 93
Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety
###end article-title 93
###begin article-title 94
###xml 149 154 <span type="species:ncbi:10090">mouse</span>
Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse
###end article-title 94
###begin article-title 95
Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness
###end article-title 95
###begin article-title 96
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
Neuron-specific enolase-cre mouse line with cre activity in specific neuronal populations
###end article-title 96
###begin article-title 97
ER-based double iCre fusion protein allows partial recombination in forebrain
###end article-title 97
###begin article-title 98
###xml 28 43 <span type="species:ncbi:10090">transgenic mice</span>
Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP
###end article-title 98
###begin article-title 99
###xml 2 7 <span type="species:ncbi:4932">yeast</span>
###xml 103 118 <span type="species:ncbi:10090">transgenic mice</span>
A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice
###end article-title 99
###begin article-title 100
Survival of DA neurons is independent of CREM upregulation in absence of CREB
###end article-title 100
###begin article-title 101
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
Codon-improved Cre recombinase (iCre) expression in the mouse
###end article-title 101
###begin article-title 102
###xml 35 50 <span type="species:ncbi:10090">transgenic mice</span>
A method for the generation of YAC transgenic mice by pronuclear microinjection
###end article-title 102

